Company Performance - Verastem reported a quarterly loss of $0.39 per share, which was better than the Zacks Consensus Estimate of a loss of $0.85, representing an earnings surprise of +54.12% [1] - The company posted revenues of $2.14 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 86.36%, compared to revenues of $10 million a year ago [2] - Over the last four quarters, Verastem has surpassed consensus EPS estimates two times but has not beaten consensus revenue estimates [2] Stock Movement and Outlook - Verastem shares have increased by approximately 10.6% since the beginning of the year, outperforming the S&P 500's gain of 7.9% [3] - The future stock price movement will largely depend on management's commentary during the earnings call and the company's earnings outlook [4][6] - The current consensus EPS estimate for the upcoming quarter is -$0.72 on revenues of $10.98 million, and for the current fiscal year, it is -$3.51 on revenues of $17.25 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Verastem belongs, is currently ranked in the top 41% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Verastem's performance [5]